Boehringer Hopes To Tap AbbVie's ''Humira Magic'' In Immunology Pact

Boehringer Ingelheim and AbbVie Inc. have launched a global collaboration to develop two of the German group's most advanced biologic compounds in immunology, a therapy field where the US-based group has acquired extensive insight from its TNF inhibitor Humira (adalimumab).